Monostory Katalin

Citokróm P450 enzimekhez köthető gyógyszer-metabolizmus a gyógyszerbiztonság tükrében

Az in vitro megközelítéstől a klinikai alkalmazásig

11. Irodalomjegyzék

Achour B, Barber J, Rostami-Hodjegan A: Expression of hepatic drug-metabolizing cytochrome P450 enzymes and their intercorrelations: a meta-analysis. Drug Metab Dispos, 42(8): 1349–1356, 2014.

Aitken AE, Morgan ET: Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos, 35(9): 1687–1693, 2007.

Akakpo JY, Ramachandran A, Jaeschke H: Novel strategies for the treatment of acetaminophen hepatotoxicity. Exp Opin Drug MetabToxicol, 16(11): 1039–1050, 2020.

Akakpo JY, Ramachandran A, Curry SC, Rumack BH, Jaeschke H: Comparing N‑acetylcysteine and 4-methylpyrazole as antidotes for acetaminophen overdose. Arch Toxicol, 96: 453–465, 2022.

Alamo C, Lopez-Munoz F: The pharmacological role and clinical applications of antipsychotics’active metabolites: paliperidone versus risperidone. Clin Exp Pharmacol, 3: 1000117, 2013.

Alexander J, Auðunsson GA, Benford D, Cockburn A, Cravedi J-P, Dogliotti E, Di Domenico A, Férnandez-Cruz ML, Fürst P, Fink-Gremmels J, Galli CL, Grandjean P, Gzyl J, Heinemeyer G, Johansson N, Mutti A, Schlatter J, van Leeuwen R, Van Peteghem C, Verger P: Cross-contamination of non-target feedingstuffs by monensin authorised for use as a feed additive. EFSA Journal, 6(1): 592, 2008.

Anderson GD: Gender differences in pharmacological response. Int Rev Neurobiol 83: 1–10, 2008.

Arguelles N, Richards J, El-Sherbeni AA, Miksys S, Tyndale RFSex, estrous cycle, and hormone regulation of CYP2D in the brain alters oxycodone metabolism and analgesia. Biochem Pharmacol, 198: 114949, 2022.

Bains RK: African variation at cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases. Evol Med Public Health, 2013(1): 118–134, 2013.

Barnes KJ, Rowland A, Polasek TM, Miners JO: Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. Eur J Clin Pharmacol, 70(9): 1097–1106, 2014.

Bayliss KM, Skett P: Isolation and culture of human hepatocytes. In Human Cell Culture Protocols (Jones GE szerk.). Humana Press, Totowa NJ, 1996, 369–390.

Benedetti SM, Bani M: Design of in vitro studies to predict in vivo inhibitory drug-drug interactions. Pharmacol Res, 38(2): 81–88, 1998.

Berry MN, Edwards AM, Barritt GJ, Grivell MB, Halls HJ, Gannon BJ, Friend DS: Initial determination of cell quality. In Isolated Hepatocytes (Berry MN, Edwards AM, Barritt GJ, Grivell MB, Halls HJ, Gannon BJ, Friend DS szerk.). Elsevier, Amsterdam, 1991, 45–47.

Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups: The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol, 43(5): 443–469, 2003.

Brown DG, Wobst HJ: A decade of FDA-approved drugs (2010–2019): Trends and future directions. J Med Chem, 64: 2312–2338, 2021.

Buchwald P, Bodor AA: A gyógynövényektől a megtervezett gyógyszerekig. Dacia Könyvkiadó, Kolozsvár, 1981.

Burns KE, Goldthorpe MA, Porteus F, Browett P, Helsby NA: CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity. Cancer Chemother Pharmacol, 73(3): 651–655, 2014.

Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF: Human cytochrome P-450PA (P‑450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3‑demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86: 7696–7700, 1989.

Casey AB, Canal CE: Classics in chemical neuroscience: Aripiprazole. ACS Chem Neurosci, 8: 1135–1146, 2017.

Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, Relling MV, Hoffman JM: Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med, 19(2): 215–223, 2017.

Cavallari LH, Jeong H, Bress A: Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med, 4: 123–136, 2011.

Chateauvieux S, Morceau F, Dicato M, Diederich M: Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol, 2010: 479364, 2010.

Chevalier D, Cauffiez C, Allorge D, Lo-Guidice JM, Lhermitte M, Lafitte JJ, Broly F: Five novel natural allelic variants - 951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y) - of the human CYP1A2 gene in a French Caucasian population. Hum Mutat, 17: 355, 2001.

Chiba M, Ishii Y, Sugiyama Y Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J, 11: 262–276, 2009.

Choudhary NS, Saigal S, Bansal RK, Saraf N, Gautam D, Soin AS: Acute and chronic rejection after liver transplantation: What a clinician needs to know. J Clin Exp Hepatol 7(4): 358–366, 2017.

Chouinard G: Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry, 65 Suppl 5: 7–12, 2004.

Christensen H, Hermann M: Immunological response as a source to variability in drug metabolism and transport. Front Pharmacol, 3: 8, 2012.

Chung TDY, Terry DB, Smith LH: In vitro assessment of ADME and PK properties during lead selection and lead optimization – Guidelines, benchmarks and rules of thumb. In Assay Guidance Manual (Markosian S, Grossman A, Brimacombe K szerk.). Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2015 (frissítve: 2021), 1385–1398.

Coleman RA, Bowen WP, Baines IA, Woodrooffe AJ, Brown AM: Use of human tissue in ADME and safety profiling of development candidates. Drug Discovery Today, 6: 1116–1126, 2001.

Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN: Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev, 13: 419–431, 2014.

Crespi CL, Miller VP, Stresser DM: Design and application of fluorometric assays for human cytochrome P450 inhibition. Methods Enzymol, 357: 276–284, 2002.

Daly AK: Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet, 45(1): 13–31, 2006.

Davies B, Morris T: Physiological parameters in laboratory animals and humans. Pharm Res, 10: 1093–1095, 1993.

Dean L, Kane M: Aripiprazole therapy and CYP2D6 genotype. In Medical Genetics Summaries (Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, Malheiro AJ szerk.). National Center for Biotechnology Information (US); 2012. (Frissítve: 2021.02.10.)

Deodhar M, Al Rihani SB, Arwood MJ, Darakjian L, Dow P, Turgeon J, Michaud V: Mechanisms of CYP450 inhibition: Understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics, 12(9): 846, 2020.

Deore AB, Dhumane JR, Wagh HV, Sonawane RB: The stages of drug discovery and development process. Asian J Pharmac Res Dev, 7(6): 62–67, 2019.

Djordjevic N, Ghotbi R, Jankovic S, Aklillu E: Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism. Eur J Clin Pharmacol, 66: 697–703, 2010.

Doerksen MJ, Jones RS, Coughtrie MWH, Collier AC: Parameterization of microsomal and cytosolic scaling factors: Methodological and biological considerations for scalar derivation and validation. Eur J Drug Metab Pharmacokinet, 46(2): 173–183, 2021.

Dogan N, Hüsing-Kabar A, Schmidt HH, Cicinnati VR, Beckebaum S, Kabar I: Acute allograft rejection in liver transplant recipients: Incidence, risk factors, treatment success, and impact on graft failure. J Int Med Res, 46(9): 3979–3990, 2018.

Duarte MP, Palma BB, Gilep AA, Laires A, Oliveira JS, Usanov SA, Rueff J, Kranendonk M: The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450 mediated biotransformation. Mutagenesis, 20(2): 93–100, 2005.

EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Bampidis, V, Azimonti G, Bastos M, Christensen H, Dusemund B, Durjava MK, Lopez-Alonso M, Puente SL, Marcon F, Mayo B, Pechova A, Petkova M, Ramos F, Sanz Y, Villa RE, Woutersen R, Bories G, Brantom P, Gropp J, Finizio A, Focks A, Teodorovic I, Glandorf B, Herman L, Maradona MP, Holzknecht O, Tarres-Call J, Vettori MV, Kouba M: Safety and efficacy of Elancoban (R) G200 (monensin sodium) for chickens for fattening, chickens reared for laying and turkeys. EFSA Journal, 17(12): e05891, 2019.

El-Sankary W, Gibson GG, Ayrton A, Plant N: Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos, 29: 1499–1504, 2001.

Fang H, Wang X, Hou K, Zhang Y, Shao S, Zhang G, Feng Y, Huang L: The association of adjusted plasma valproic acid concentration with CYP2C9 gene polymorphism in patients with epilepsy: a systematic review and meta-analysis. Ann Transl Med, 9(10): 846, 2021.

Fang J, Coutts RT, McKenna KF, Baker GB: Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol, 358: 592–599, 1998.

Fanni D, Pinna F, Gerosa C, Paribello P, Carpiniello B, Faa G, Manchia M: Anatomical distribution and expression of CYP in humans: Neuropharmacological implications. Drug Dev Res, 82(5): 628–667, 2021.

Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon CS, Dykeman J, Pringsheim T, Lorenzetti DL, Jetté N: Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology, 88(3): 296–303, 2017.

Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, Cherrington NJ: Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos, 37(10): 2087–2094, 2009.

Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshé SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S: ILAE official report: a practical clinical definition of epilepsy. Epilepsia, 55(4): 475–482, 2014.

Fogarasi A, Neuwirth M, Gyorsok Z, Czirják S, Vajda J, Bognár L: Epilepsy surgery in childhood: theory and practice. Orv Hetil, 144(48): 2359–2365, 2003.

Fowler S, Morcos PN, Cleary Y, Martin-Facklam M, Parrott N, Gertz M, Yu L: Progress in prediction and interpretation of clinically relevant metabolic drug-drug interactions: a minireview illustrating recent developments and current opportunities. Curr Pharmacol Rep, 3(1): 36–49, 2017.

Franco V, Perucca E: The pharmacogenomics of epilepsy. Expert Rev Neurother, 15: 1161–1170, 2015.

Fricke-Galindo I, Céspedes-Garro C, Rodrigues-Soares F, Naranjo ME, Delgado Á, de Andrés F, López-López M, Peñas-Lledó E, LLerena A: Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations. Pharmacogenomics J, 16(2): 113–123, 2016.

Friede KA, Ginsburg GS, Voora D: Gene expression signatures and the spectrum of coronary artery disease. J Cardiovasc Transl Res, 8: 339–352, 2015.

Fujino C, Sanoh S, Katsura T: Variation in expression of cytochrome P450 3A isoforms and toxicological effects: Endo- and exogenous substances as regulatory factors and substrates. Biol Pharm Bull, 44(11): 1617–1634, 2021.

Furberg CD, Pitt B: Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med, 2(5): 205–207, 2001.

Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE; PharmVar Steering Committee: The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther, 103(3): 399–401, 2018.

Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE: Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics, 23(4): 236–241, 2013.

Ghotbi R, Christensen M, Roh H-K, Ingelman-Sundberg M, Aklillu E, Bertilsson L: Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol, 63: 537–546, 2007.

Gilman AG, Goodman LS, Rall TW, Murad F: Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 7. kiadás, Macmillan Publishing Company, New York, 1985.

Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M, Smolenski S, Goble R: Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci, 66: 185–200, 2002.

Go AS: Cardiovascular disease consequences of CKD. Semin Nephrol, 36(4): 293–304, 2016.

Gotoh S, Ohno M, Yoshinari K, Negishi M, Kawajiri K: Nuclear receptor-mediated regulation of cytochrome P450 genes. In Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano PR szerk.). Springer, Heidelberg 2015, 787–812.

Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ: Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem, 261: 5051–5060, 1986.

Guengerich FP: Cytochrome P450 and chemical toxicology. Chem Res Toxicol, 21: 70–83, 2008.

Guengerich FP: Human cytochrome P450 enzymes. In Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano PR szerk.). Springer, Heidelberg, 2015, 523–785.

Guerrini, R: Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs, 8: 113–129, 2006.

Hahn M, Roll SC: The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug-drug interactions: drug-gene, drug-gene-gene and drug-drug-gene interactions. Pharmaceuticals (Basel), 14(5): 487, 2021.

Hakkola J, Bernasconi C, Coecke S, Richert L, Andersson TB, Pelkonen O: Cytochrome P450 induction and xeno-sensing receptors pregnane X receptor, constitutive androstane receptor, aryl hydrocarbon receptor and peroxisome proliferator-activated receptor α at the crossroads of toxicokinetics and toxicodynamics. Basic Clin Pharmacol Toxicol 123 Suppl 5: 42–50, 2018.

Hakkola J, Hukkanen J, Turpeinen M, Pelkonen O: Inhibition and induction of CYP enzymes in humans: an update. Arch Toxicol, 94(11): 3671–3722, 2020.

Hannemann F, Bichet A, Ewen KM, Bernhardt R: Cytochrome P450 systems – biological variations of electron transport chains. Biochim Biophys Acta, 1770(3): 330–344, 2007.

Hägglöf I, Holmgren A: Regulatory affairs. In Drug Discovery and Development. Technology Transition (Rang HP, Hill RG szerk.). Elsevier, London, 2013, 285–301.

He ZX, Chen XW, Zhou ZW, Zhou SF: Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine. Drug Metab Rev, 47(4): 470–519, 2015.

Hein DW: N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin Drug Metab Toxicol, 5(4): 353–366, 2009.

Hein DW, Millner LM: Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy – a focused review. Expert Opin Drug Metab Toxicol, 17(1): 9–21, 2021.

Herrero MJ, Megias J, Bosó V, Ruiz J, Rojas L, Sanchez-Lazaro I, Amenar L, Hernandez J, Poveda JL, Pastor A, Solé A, Lopez-Andujar R, Alino SF: Pharmacogenetics of immunosuppressants in solid organ transplantation: Time to implement in the clinic. In Frontiers in Transplantology (Abdeldayem H, El-Kased AF, El-Shaarawy A szerk.). InTechOpen, 2016. 99–131.

Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM, Hengstler JG: Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev, 39(1): 159–234, 2007.

Heyn H, White RB, Stevens JC: Catalytic role of cytochrome P4502B6 in the N‑demethylation of S-mephenytoin. Drug Metab Dispos, 24: 948–954, 1996.

Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G: AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry, 44: 195–235, 2011.

Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P: Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry, 51(01–02): 6–92, 2018.

Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, Hobbs FD: Global prevalence of chronic kidney disease – A systematic review and meta-analysis. PLoS One, 11(7): e0158765, 2016.

van der Hoeven TA, Coon MJ: Preparation and properties of partially purified cytochrome P450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem, 249: 6302–6310, 1974.

Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR: Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA, 269(12): 1513–1518, 1993.

Huang W, Lin YS, McConn DJ 2nd, Calamia JC, Totah RA, Isoherranen N, Glodowski M, Thummel KE: Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos, 32(12): 1434–1445, 2004.

Huang SM, Lesko LJ: Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J Clin Pharmacol, 44(6): 559–569, 2004.

Hukkanen J: Induction of cytochrome P450 enzymes: a view on human in vivo findings. Expert Rev Clin Pharmacol, 5(5): 569–585, 2012.

Iannaccone T, Sellitto C, Manzo V, Colucci F, Giudice V, Stefanelli B, Iuliano A, Corrivetti G, Filippelli A: Pharmacogenetics of carbamazepine and valproate: Focus on polymorphisms of drug metabolizing enzymes and transporters. Pharmaceuticals (Basel), 14(3): 204, 2021.

Ing Lorenzini K, Desmeules J, Rollason V, Bertin S, Besson M, Daali Y, Samer CF: CYP450 genotype-phenotype concordance using the Geneva micrococktail in a clinical setting. Front Pharmacol, 12: 730637, 2021.

Ingelman-Sundberg M: Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharm J, 5(1): 6–13, 2005.

Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther, 116(3): 496–526, 2007.

Ingelman-Sundberg M, Sim SC: Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochem Biophys Res Commun, 396(1): 90–94, 2010.

Iniesta I: Hippocratic Corpus. BMJ, 342: d688, 2011.

Ioannides C: Xenobiotic metabolism: An overview. In Enzyme Systems that Metabolise Drugs and Other Xenobiotics (Ioannides C szerk.). John Wiley & Sons, Ltd., Chichester UK, 2001, 1–32.

Jain KK: Applications of AmpliChip CYP450. Mol Diagn, 9(3): 119–127, 2005.

John AP, Kecanovic A: Unusually high serum levels of clozapine associated with genetic polymorphism of CYP3A enzymes. Asian J Psychiatr, 57: 102126, 2021

Kamdem LK, Streit F, Zanger UM, Brockmöller J, Oellerich M, Armstrong VW, Wojnowski L: Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem, 51(8): 1374–1381, 2005.

Kane JM, Kim E, Kan HJ, Guo Z, Bates JA, Whitehead R, Pikalov A: Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. Appl Health Econ Health Policy, 7(2): 109–119, 2009.

Kantae V, Krekels EHJ, Esdonk MJV, Lindenburg P, Harms AC, Knibbe CAJ, Van der Graaf PH, Hankemeier T: Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. Metabolomics, 13(1): 9, 2017.

Karamichos D, Escandon P, Vasini B, Nicholas SE, Van L, Dang DH, Cunningham RL, Riaz KM: Anterior pituitary, sex hormones, and keratoconus: Beyond traditional targets. Prog Retin Eye Res, 88: 101016, 2022.

Kazmi SR, Jun R, Yu M-S, Jung C, Na D: In silico approaches and tools for the prediction of drug metabolism and fate: A review. Comput Biol Med, 106: 54–64, 2019.

Khanna I: Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Disc Today, 17(19/20): 1088–1102, 2012.

Kiang TKL, Ho PC, Anari MR, Tong V, Abbott FS, Chang TKH: Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci, 94(2): 261–271, 2006.

Kim TH, Shin S, Shin BS: Model-based drug development: application of modeling and simulation in drug development. J Pharm Investig, 48: 431–441, 2018.

Kirschbaum KM, Müller MJ, Malevani J, Mobascher A, Burchardt C, Piel M, Hiemke C: Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry, 9: 212–218, 2008.

Klinge CM, Clark BJ, Prough RA: Dehydroepiandrosterone research: Past, current, and future. Vitam Horm, 108: 1–28, 2018.

Klomp SD, Manson ML, Guchelaar HJ, Swen JJ: Phenoconversion of cytochrome P450 metabolism: A systematic review. J Clin Med, 9(9): 2890, 2020.

Knights KM, Stresser DM, Miners JO, Crespi CL: In vitro drug metabolism using liver microsomes. Curr Protoc Pharmacol, 74: 7.8.1–7.8.24, 2016.

Kobayashi K, Yamanaka Y, Iwazaki N, Nakajo I, Hosokawa M, Negishi M, Chiba K: Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos, 33: 924–929, 2005.

Kocarek TA, Dahn MS, Cai H, Strom SC, Mercer-Haines NA: Regulation of CYP2B6 and CYP3A4 expression by hydroxymethylglutaryl coenzyme A reductase inhibitors in primary cultured human hepatocytes. Drug Metab Dispos, 30: 1400–1405, 2002.

Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov, 3(8): 711–716, 2004.

Koop DR, Laethem CL, Tierney DJ: The utility of p-nitrophenol hydroxylation in P450IIE1 analysis. Drug Metab Rev, 20(2–4): 541–551, 1989.

Kovács G: A szkizofrénia gyógyszeres kezelése. Neuropsychopharmacol Hung, 13(4): 239–247, 2011.

Krajcsi P: Drug-transporter interaction testing in drug discovery and development. World J Pharmacol, 2(1): 35–46, 2013.

Kremers P: Can drug-drug interactions be predicted from in vitro studies? Sci World J, 2: 751–766, 2002.

Kronbach T, Mathys D, Gut J, Catin T, Meyer UA: High-performance liquid chromatographic assays for bufuralol 1’-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem, 162: 24–32, 1987.

Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer U: Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol, 36: 89–96, 1989.

Kurzawski M, Drozdzik M. Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs. Pharmacogenomics, 14: 1099–1118, 2013.

Lai XS, Yang LP, Li XT, Liu JP, Zhou ZW, Zhou SF: Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr Drug Metab, 10(9): 1009–1047, 2009.

Lameh J, Burstein ES, Taylor E: Pharmacology of N-desmethylclozapine. Pharmacol Ther, 115: 223–231, 2007.

Langhammer AJ, Nilsen OG: Fennel and raspberry leaf as possible inhibitors of acetaminophen oxidation. Phytother Res, 28: 1573–1576, 2014.

Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM: Clinical pharmacokinetics in kidney disease: Fundamental principles. Clin J Am Soc Nephrol, 13(7): 1085–1095, 2018.

Lenoir C, Rollason V, Desmeules JA, Samer CF: Influence of inflammation on cytochromes P450 activity in adults: A systematic review of the literature. Front Pharmacol, 12: 733935, 2021.

de Leon J, Diaz FJ: A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res, 76: 135–157, 2005.

Leucht S, Busch R, Kissling W, Kane JM: Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry, 68: 352–360, 2007.

Lewis DFV: Guide to Cytochromes P450. Structure and Function. Taylor & Francis, London, 2001.

Li AP, Maurel P, Gomez-Lechon MJ, Cheng LC, Jurima-Romet M: Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem Biol Interact, 107(1–2): 5–16, 1997.

Lombardo FC, Ravaynia PS, Modena MM, Hierlemann A, Keiser J: Evaluation of human liver microtissues for drug screening on Schistosoma mansoni Schistosomula. ACS Infect Dis, 7(7): 1894–1900, 2021.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with Folin reagent. J Biol Chem, 193: 265–275, 1951.

Lu C, Di L: In vitro and in vivo methods to assess pharmacokinetic drug-drug interactions in drug discovery and development. Biopharm Drug Dispos, 41(1–2): 3–31, 2020.

Lu ML, Lane HY, Chen KP, Jann MW, Su MH, Chang WH: Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. Clin Psychiatry, 61: 594–599, 2000.

Lu ML, Lane HY, Lin SK, Chen KP, Chang WH: Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry, 65: 766–771, 2004.

Ludwig E, Schmid J, Beschke K, Ebner T: Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5’-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther, 290(1): 1–8, 1999.

Magro L, Arzenton E, Leone R, Stano MG, Vezzaro M, Rudolph A, Castagna I, Moretti U: Identifying and characterizing serious adverse drug reactions associated with drug-drug interactions in a spontaneous reporting database. Front Pharmacol, 11: 622862, 2021.

Mandagere AK: Strategies in lead selection and optimization: Application of a graphical model and automated in vitro ADME screening. Pharmacokinetic Challenges in Drug Discovery (Pelkonen O, Baumann A, Reichel A szerk.). Springer-Verlag, Berlin, 2002, 185–202.

Manikandan P, Nagini S: Cytochrome P450 structure, function and clinical significance: A review. Curr Drug Targets, 19(1): 38–54, 2018.

Mann B, Melton R, Thompson D: Drug metabolism in drug discovery and preclinical development. In Drug Metabolism (Dunnington K szerk.). IntechOpen, London, 2021, 1–14.

Martinez MN, Antonovic L, Court M, Dacasto M, Fink-Gremmels J, Kukanich B, Locuson C, Mealey K, Myers MJ, Trepanier L: Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics. Drug Metab Rev, 45: 218–230, 2013.

Masuda S, Inui K: An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther, 112(1): 184–198, 2006.

Matsunaga T, Maruyama M, Matsubara T, Nagata K, Yamazoe Y, Ohmori S: Mechanisms of CYP3A induction by glucocorticoids in human fetal liver cells. Drug Metab Pharmacokinet, 27(6): 653–657, 2012.

Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR: Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet, 46: 359–388, 2007.

McDonagh EM, Boukouvala S, Aklillu E, Hein DW, Altman RB, Klein TE: PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. Pharmacogenet Genomics, 24: 409–425, 2014.

McElvaney OJ, McEvoy NL, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM, Ní Choileáin O, Clarke J, O'Connor E, Hogan G, Ryan D, Sulaiman I, Gunaratnam C, Branagan P, O'Brien ME, Morgan RK, Costello RW, Hurley K, Walsh S, de Barra E, McNally C, McConkey S, Boland F, Galvin S, Kiernan F, O'Rourke J, Dwyer R, Power M, Geoghegan P, Larkin C, O'Leary RA, Freeman J, Gaffney A, Marsh B, Curley GF, McElvaney NG: Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med, 202(6): 812–821, 2020.

Mei S, Feng W, Zhu L, Yu Y, Yang W, Gao B, Wu X, Zhao Z, Fang F: Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy. Seizure, 51: 22–26, 2017.

Mendonça Júnior FJ, Scotti L, Ishiki H, Botelho SP, Da Silva MS, Scotti MT: Benzo- and thienobenzo-diazepines: multi-target drugs for CNS disorders. Mini Rev Med Chem, 15: 630–647, 2015.

Merrell MD, Cherrington NJ: Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev, 43(3): 317–334, 2011.

Michalets EL, Williams CR: Drug interactions with cisapride: clinical implications. Clin Pharmacokinet, 39(1): 49–75, 2000.

Michaud J, Naud J, Chouinard J, Désy F, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V: Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J Am Soc Nephrol, 17(11): 3041–3048, 2006.

Mikudina B, Érsek K, Arányi Zs, Juhos V, Gulácsi L: Epilepszia betegségteher felmérés Magyarországon. In Gondolatok közös javainkról. A Budapesti Corvinus Egyetem, Közgazdaságtudományi Kar 2010. évi konferenciája (Budapest, 2010.04.27.). 2011, 179–187.

Miller CH, Fleischhacker WW: Managing antipsychotic-induced acute and chronic akathisia. Drug Saf, 22: 73–81, 2000.

Miners JO, Birkett DJ: Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods Enzymol, 272: 139–145, 1996.

Mohs RC, Greig NH: Drug discovery and development: Role of basic biological research. Alzheimers Dement (N Y), 3(4): 651–657, 2017.

Momper JD, Venkataramanan R, Nolin TD: Nonrenal drug clearance in CKD: Searching for the path less traveled. Adv Chronic Kidney Dis, 17(5): 384–391, 2010.

Monostory K, Vereczkey L: In vitro - in vivo correlation of CYP1A induction. Exp Toxicol Pathol, 48 suppl II: 291–294, 1996.

Moorthy B, Sriram P, Pathak DN, Bodell WJ, Raderath K: Tamoxifen metabolic activation: comparision of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res, 56: 53–57, 1996.

Morgan ET: Regulation of drug-metabolizing enzymes and drug metabolism by inflammatory responses. In Drug Metabolism in Diseases (Xie W szerk.). Academic Press, 2017, 21–58.

Mroz P, Michel S, Allen JD, Meyer T, McGonagle EJ, Carpentier R, Vecchia A, Schlichte A, Bishop JR, Dunnenberger HM, Yohe S, Thyagarajan B, Jacobson PA, Johnson SG: Development and implementation of in-house pharmacogenomic testing program at a major academic health system. Front Genet, 12: 712602, 2021.

Mullen Grey AK, Riddick DS: Glucocorticoid and adrenalectomy effects on the rat aryl hydrocarbon receptor pathway depend on the dosing regimen and post-surgical time. Chem-Biol Interact, 182:148–158, 2009.

Murphy CS, Parker CJ, McCague R, Jordan CV: Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity. Mol Pharmacol, 39: 421–428, 1991.

Musunuru K, Ingelsson E, Fornage M, Liu P, Murphy AM, Newby LK, Newton-Cheh C, Perez MV, Voora D, Woo D; American Heart Association Committee on Molecular Determinants of Cardiovascular Health of the Council on Functional Genomics and Translational Biology and Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology; and Stroke Council: The expressed genome in cardiovascular diseases and stroke: Refinement, diagnosis, and prediction: A scientific statement from the American Heart Association. Circ Cardiovasc Genet, 10(4). pii: e000037, 2017.

Nanau RM, Neuman MG: Adverse drug reactions induced by valproic acid. Clin Biochem, 46(15): 1323–1338, 2013.

Nardi AE, Perna G: Clonazepam in the treatment of psychiatric disorders: an update. Int Clin Psychopharmacol, 21: 131–142, 2006.

Nardi AE, Freire RC, Valença AM, Amrein R, de Cerqueira AC, Lopes FL, Nascimento I, Mezzasalma MA, Veras AB, Sardinha A, de Carvalho MR, da Costa RT, Levitan MN, de-Melo-Neto VL, Soares-Filho GL, Versiani M: Tapering clonazepam in patients with panic disorder after at least 3 years of treatment. J Clin Psychopharmacol, 30: 290–293, 2010.

Nelson DR: Cytochrome P450 nomenclature, 2004. In Cytochrome P450 Protocols (Phillips IR, Shephard EA szerk.) Methods in Molecular Biology, vol. 320. Humana Press, Totowa NJ, 2006, 1–10.

Nemes B, Szederkényi E, Nagy KK, Hartyánszky I, Ablonczy L, Vámos FR, Mihály S, Máthé Z: A summary of transplantation activity in Hungary. Transplant Proc, 51(4): 1202–1208, 2019.

Niklas J, Diaz Ochoa JG, Bucher J, Mauch K: Quantitative evaluation and prediction of drug effects and toxicological risk using mechanistic multiscale models. Mol Inform, 32: 14–23, 2013.

Niwa T, Inoue-Yamamoto S, Shiraga T, Takagi A: Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biological & Pharmaceutical Bulletin, 28: 1813–1816, 2005.

Niwa T, Yamazaki H: Comparison of cytochrome P450 2C subfamily members in terms of drug oxidation rates and substrate inhibition. Curr Drug Metab, 13(8): 1145–1159, 2012.

Obach RS: Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos, 27: 1350–1359, 1999.

Ojo AO: Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol, 27(4): 498–507, 2007.

Olesen OV, Linnet K: Contributions of five human cytochrome P450 isoforms to the N‑demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol, 41: 823–832, 2001.

Olivera M, Martínez C, Gervasini G, Carrillo JA, Ramos S, Benítez J, García-Martin E, Agúndez JA: Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett, 1: 3–5, 2007.

Omura T, Sato R: The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem, 239: 2370–2378, 1964.

Owen MJ, Sawa A, Mortensen PB: Schizophrenia. Lancet, 388(10039): 86–97, 2016.

Pantaleão SQ, Fernandes PO, Gonçalves JE, Maltarollo VG, Honorio KM: Recent advances in the prediction of pharmacokinetics properties in drug design studies: A review. ChemMedChem, 17(1): e202100542, 2022.

Pariente A, Dartigues JF, Benichou J, Letenneur L, Moore N, Fourrier-Réglat A: Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging, 25: 61–70, 2008.

Parkinson A, Kazmi F, Buckley DB, Yerino P, Ogilvie BW, Paris BL: System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes. Drug Metab Pharmacokinet, 25(1): 16–27, 2010.

Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre JM, Maurel P, Vilarem MJ: Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun, 274(3): 707–713, 2000.

Pascussi JM, Busson-Le Coniat M, Maurel P, Vilarem MJ: Transcriptional analysis of the orphan nuclear receptor constitutive androstane receptor (NR1I3) gene promoter: identification of a distal glucocorticoid response element. Mol Endocrinol, 17(1): 42–55, 2003a.

Pascussi JM, Dvorák Z, Gerbal-Chaloin S, Assenat E, Maurel P, Vilarem MJ: Pathophysiological factors affecting CAR gene expression. Drug Metab Rev, 35(4): 255–268, 2003b.

Pascussi JM, Gerbal-Chaloin S, Duret C, Daujat-Chavanieu M, Vilarem MJ, Maurel P: The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol, 48: 1–32, 2008.

Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H: Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol, 82(10): 667–715, 2008.

Pelkonen O, Hakkola J, Hukkanen J, Turpeinen M: CYP-associated drug-drug interactions: A mission accomplished? Arch Toxicol, 94(11): 3931–3934, 2020.

Perera V, Gross AS, McLachlan AJ: Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry. Clin Pharmacol Ther, 92: 511–519, 2012.

Peter R, Böcker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol, 3: 566–573, 1990.

Peterson GM, Naunton M. Valproate: a simple chemical with so much to offer. J Clin Pharm Ther, 30(5): 417–421, 2005.

Petrovska BB: Historical review of medicinal plants’ usage. Pharmacogn Rev, 6(11): 1–5, 2012.

Polasek TM, Lin FP, Miners JO, Doogue MP: Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol, 71(5): 727–736, 2011.

Polcwiartek C, Nielsen J: The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. Psychopharmacology (Berl), 233: 741–750, 2016.

Powell NR, Liang T, Ipe J, Cao S, Skaar TC, Desta Z, Qian HR, Ebert PJ, Chen Y, Thomas MK, Chalasani N: Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease. Nat Commun, 14(1): 1474, 2023.

Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D: Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol, 49 Suppl 1: 35S–42S, 2000.

Prough RA, Clark BJ, Klinge CM: Novel mechanisms for DHEA action. J Mol Endocrinol, 56(3): R139–155, 2016.

Rang HP, Hill RG: Drug development: Introduction. In Drug Discovery and Development. Technology Transition (Rang HP, Hill RG szerk.). Elsevier, London, 2013a, 203–209.

Rang HP, Hill RG: Drug discovery and development: facts and figures. Drug Discovery and Development. Technology Transition (Rang HP, Hill RG szerk.). Elsevier, London, 2013b, 321–334.

Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE, Kelloff GJ, McCormick DL: Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res, 59(13): 3084–3089, 1999.

Reinke LA, Moyer MJ: p-Nitrophenol hydroxylation. A microsomal oxidation which is highly inducible by ethanol. Drug Metab Dispos, 13(5): 548–552, 1985.

Rendic S, Di Carlo FJ: Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev, 29(1–2): 413–580, 1997.

Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev, 34(1–2): 83–448, 2002.

Rendic S, Guengerich FP: Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol, 25(7): 1316–1383, 2012.

Rendic S, Guengerich FP: Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update. Arch Toxicol, 95(2): 395–472, 2021.

Ripp SL, Fitzpatrick JL, Peters JM, Prough RA: Induction of CYP3A expression by dehydroepiandrosterone: involvement of the pregnane X receptor. Drug Metab Dispos, 30(5): 570–575, 2002.

Ripp SL, Falkner KC, Pendleton ML, Tamasi V, Prough RA: Regulation of CYP2C11 by dehydroepiandrosterone and peroxisome proliferators: identification of the negative regulatory region of the gene. Mol Pharmacol, 64(1): 113–122, 2003.

Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand, 118: 69–86, 2008.

Roberts DM, Sevastos J, Carland JE, Stocker SL, Lea-Henry TN: Clinical pharmacokinetics in kidney disease: Application to rational design of dosing regimens. Clin J Am Soc Nephrol, 13(8): 1254–1263, 2018.

Rodriguez-Antona C, Savieo JL, Lauschke VM, Sangkuhl K, Drögemöller BI, Wang D, van Schaik RHN, Gilep AA, Peter AP, Boone EC, Ramey BE, Klein TE, Whirl-Carrillo M, Pratt VM, Gaedigk A: PharmVar GeneFocus: CYP3A5. Clin Pharmacol Ther, 2022. doi: 10.1002/cpt.2563.

Sachse C, Brockmöller J, Bauer S, Roots I: Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol, 47: 445–449, 1999.

Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, Garner RC, Boobis AR, Wolf CR, Gooderham NJ; Colorectal Cancer Study Group: Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol, 55(1): 68–76, 2003.

Santes-Palacios R, Ornelas-Ayala D, Cabañas N, Marroquín-Pérez A, Hernández-Magaña A, Del Rosario Olguín-Reyes S, Camacho-Carranza R, Espinosa-Aguirre JJ: Regulation of human cytochrome P4501A1 (hCYP1A1): A plausible target for chemoprevention? Biomed Res Int, 2016: 5341081, 2016.

Scandlyn MJ, Stuart EC, Rosengren RJ: Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol, 4(4): 413–424, 2008.

Sevrioukova IF, Poulos TL: Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. Dalton Trans, 42(9): 3116–3126, 2013.

Shah KR, Beuhler MC: Fomepizole as an adjunctive treatment in severe acetaminophen toxicity. Am J Emerg Med, 38(2): 410.e5–410.e6, 2020.

Shah KR, Fox C, Geib AJ, Murphy C, Kopec K, Kerns Ii W, Dulaney A, Beuhler MC: Fomepizole as an adjunctive treatment in severe acetaminophen ingestions: a case series. Clinical Toxicology (Phila), 59(1):71–72, 2021.

Shah RR, Smith RL: Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br J Clin Pharmacol, 79(2): 222–240, 2015a.

Shah RR, Smith RL: Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos, 43(3): 400–410, 2015b.

Shah RR, Gaedigk A, LLerena A, Eichelbaum M, Stingl J, Smith RL: CYP450 genotype and pharmacogenetic association studies: a critical appraisal. Pharmacogenomics, 17(3): 259–275, 2016.

Shekhani R, Steinacher L, Swen JJ, Ingelman-Sundberg M: Evaluation of current regulation and guidelines of pharmacogenomic drug labels: Opportunities for improvements. Clin Pharmacol Ther, 107(5): 1240–1255, 2020.

Sherratt AJ, Banet DE, Prough RA: Glucocorticoid regulation of polycyclic aromatic hydrocarbon induction of cytochrome P450IA1, glutathione S-transferases, and NAD(P)H:quinone oxidoreductase in cultured fetal rat hepatocytes. Mol Pharmacol, 37(2): 198–205, 1990.

Shukla R, Handa M, Pardhi VP: Introduction to pharmaceutical product development. In Pharmaceutical Drug Product Development and Process Optimization (Beg S, Rahman M, Imam SS, Alruwaili NK, Robaian MA, Panda SK szerk.). Apple Academic Press Inc., Palm Bay FL, 2020, 1–32.

Silva MF, Aires CC, Luis PB, Ruiter JP, IJlst L, Duran M, Wanders RJ, Tavares de Almeida I: Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis, 31(2): 205–216, 2008.

Sim SC, Ingelman-Sundberg M: Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci, 32(2): 72–81, 2011.

Singleton DW, Lei XD, Webb SJ, Prough RA, Geoghegan TE: Cytochrome P-450 mRNAs are modulated by dehydroepiandrosterone, nafenopin, and triiodothyronine. Drug Metab Dispos, 27(2): 193–200, 1999.

Sohlenius-Sternbeck AK: Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. Toxicol in Vitro, 20: 1582–1586, 2006.

Solecki RS: Shanidar IV, a Neanderthal flower burial in Northern Iraq. Science, 190: 880–881, 1975.

Srivastava PK, Yun C-H, Beaune PH, Ged C, Guengerich FP: Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4’-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol, 40: 69–79, 1991.

Staatz C, Taylor P, Tett S: Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant, 16(9): 1905–1909, 2001.

Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R; French Society of Pharmacology and Therapeutics: Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment. Pharmacol Ther, 215: 107627, 2020.

Sudsakorn S, Bahadduri P, Fretland J, Lu C: 2020 FDA drug-drug interaction guidance: A comparison analysis and action plan by pharmaceutical industrial scientists. Curr Drug Metab, 21(6): 403–426, 2020.

Swainston Harrison T, Perry CM: Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs, 64(15): 1715–1736, 2004.

Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk AM, Houwink EJF, Mulder H, Rongen GA, van Schaik RHN, van der Weide J, Wilffert B, Deneer VHM, Guchelaar HJ; Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP): Pharmacogenetic information in clinical guidelines: The European perspective. Clin Pharmacol Ther, 103(5): 795–801, 2018.

Tanaka E: In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther, 23(4): 247–255, 1998.

Tanner JA, Tyndale RF: Variation in CYP2A6 activity and personalized medicine. J Pers Med, 7(4): 18, 2017.

Teh LK, Bertilsson L: Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet, 27(1): 55–67, 2012.

Thomas JE, Caballero J, Harrington CA: The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis. Curr Neuropharmacol, 13: 681–691, 2015.

Tihanyi K, Bakk ML, Hellinger E, Vastag M: CYP inhibition-mediated drug-drug interactions. Curr Enzyme Inhibition, 6(3): 130–145, 2010.

Tornio A, Filppula AM, Niemi M, Backman JT: Clinical studies on drug-drug interactions involving metabolism and transport: Methodology, pitfalls, and interpretation. Clin Pharmacol Ther, 105(6): 1345–1361, 2019.

Turman CM, Hatley JM, Ryder DJ, Ravindranath V, Strobel HW: Alternative splicing within the human cytochrome P450superfamily with an emphasis on the brain: the convolution continues. Expert Opin Drug Metab Toxicol, 2(3): 399–418, 2006.

Turpeinen M, Raunio H, Pelkonen O: The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr Drug Metab, 7(7): 705–714, 2006.

Uludag IF, Bilgin S, Zorlu Y, Tuna G, Kirkali G: Interleukin-6, interleukin-1 beta and interleukin-1 receptor antagonist levels in epileptic seizures. Seizure, 22(6): 457–461, 2013.

Varnai R, Szabo I, Tarlos G, Szentpeteri LJ, Sik A, Balogh S, Sipeky C: Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view. Pharmacogenomics J, 20(3): 380–387, 2020.

Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, Scheller D, Ersfeld D, Frick M, Fitzsimmons WE, Virji M, Jain A, Brayman KL, Shaked A: Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol, 41(5): 542–551, 2001.

Wang SH, Liang CT, Liu YW, Huang MC, Huang SC, Hong WF, Su JG: Crosstalk between activated forms of the aryl hydrocarbon receptor and glucocorticoid receptor. Toxicology, 262: 87–97, 2009.

Waring RH: Cytochrome P450: genotype to phenotype. Xenobiotica, 50(1): 9–18, 2020.

van der Weide J, Steijns LS, van Weelden MJ: The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics, 13: 169–172, 2003.

Wenthur CJ, Lindsley CW: Classics in chemical neuroscience: clozapine. ACS Chem Neurosci, 4(7): 1018–1025, 2013.

White PF: Perioperative Drug Manual. 2. kiadás, Elsevier, Philadelphia PA, 2005.

Wiciński M, Węclewicz MM: Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring. Curr Opin Hematol, 25(1): 22–28, 2018.

Wienkers LC, Heath TG: Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov, 4(10): 825–833, 2005.

de Wildt SN, Tibboel D, Leeder JS: Drug metabolism for the paediatrician. Arch Dis Child, 99(12): 1137–1142, 2014.

Wilkening S, Stahl F, Bader A: Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard to their biotransformation properties. Drug Metab Dispos, 31(8): 1035–1042, 2003.

Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos, 30(8): 883–891, 2002.

Wiśniowska B, Tylutki Z, Wyszogrodzka G, Polak S: Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect – comprehensive overview of clinical trials. BMC Pharmacol Toxicol, 17: 12, 2016.

Woolsey SJ, Mansell SE, Kim RB, Tirona RG, Beaton MD: CYP3A activity and expression in nonalcoholic fatty liver disease. Drug Metab Dispos, 43(10): 1484–1490, 2015.

van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium: Implementing pharmacogenomics in Europe: Design and implementation strategy of the Ubiquitous Pharmacogenomics Consortium. Clin Pharmacol Ther, 101(3): 341–358, 2017.

Xiao GH, Pinaire JA, Rodrigues AD, Prough RA: Regulation of the Ah gene battery via Ah receptor-dependent and independent processes in cultured adult rat hepatocytes. Drug Metab Dispos, 23(6): 642–650, 1995.

Xu ZY, Guo HL, Li L, Zhang M, Jing X, Xu ZJ, Qiu JC, Lu XP, Ding XS, Chen F, Xu J: Genetic and non-genetic factors contributing to the significant variation in the plasma trough concentration-to-dose ratio of valproic acid in children with epilepsy. Front Pediatr, 8: 599044, 2021.

Yamamoto T, Suzuki A, Kohno Y: High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes. Xenobiotica, 33:823–839, 2003.

Yamamoto Y, Takahashi Y, Imai K, Mishima N, Yazawa R, Inoue K, Itoh K, Kagawa Y, Inoue Y: Risk factors for hyperammonemia in pediatric patients with epilepsy. Epilepsia, 54(6): 983–989, 2013.

Yamazaki H, Shimada T: Comparative studies of in vitro inhibition of cytochrome P4503A4-dependent testosterone 6β-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos, 26: 1053–1057, 1998.

Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, Rane A: Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun, 299: 25–28, 2002.

Yeung CK, Shen DD, Thummel KE, Himmelfarb J: Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int, 85(3): 522–528, 2014.

Yoo SE, Yi M, Kim WY, Cho SA, Lee SS, Lee SJ, Shin JG. Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4. Drug Metab Pharmacokinet, 34(3): 201–208, 2019.

Yu N, Di Q, Hu Y, Zhang YF, Su LY, Liu XH, Li LC: A meta-analysis of pro-inflammatory cytokines in the plasma of epileptic patients with recent seizure. Neurosci Lett, 514(1): 110–115, 2012.

Yusufi B, Mukherjee S, Flanagan R, Paton C, Dunn G, Page E, Barnes TR: Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol, 22(4): 238–243, 2007.

Zanger UM, Turpeinen M, Klein K, Schwab M: Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem, 392(6): 1093–1108, 2008.

Zanger UM, Schwab M: Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther, 138(1): 103–141, 2013.

Zanger UM, Klein K, Thomas M, Rieger JK, Tremmel R, Kandel BA, Klein M, Magdy T: Genetics, epigenetics, and regulation of drug-metabolizing cytochrome P450 enzymes. Clin Pharmacol Ther, 95(3): 258–261, 2014.

Zhang F, Li J, Na S, Wu J, Yang Z, Xie X, Wan Y, Li K, Yue J: The involvement of PPARs in the selective regulation of brain CYP2D by growth hormone. Neuroscience, 379: 115–125, 2018.

Zhang H, Davis CD, Sinz MW, Rodrigues AD: Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol, 3(5): 667–687, 2007.

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr Med Chem, 16(27): 3480–3675, 2009a.

Zhou SF, Liu JP, Chowbay B: Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev, 41(2): 89–295, 2009b.

Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther, 102(4): 688–700, 2017.

Zhou ZW, Chen XW, Sneed KB, Yang YX, Zhang X, He ZX, Chow K, Yang T, Duan W, Zhou SF: Clinical association between pharmacogenomics and adverse drug reactions. Drugs, 75(6): 589–631, 2015.

Zuber R, Anzenbacherová E, Anzenbacher P: Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med, 6: 189–198, 2002.

Citokróm P450 enzimekhez köthető gyógyszer-metabolizmus a gyógyszerbiztonság tükrében

Tartalomjegyzék

Kiadó: Akadémiai Kiadó

Online megjelenés éve: 2025

ISBN: 978 963 664 152 8

Biológia

A gyógyszerbiztonság megteremtésének része a gyógyszer-metabolizmusban mutatkozó egyéni eltérések és farmakokinetikai gyógyszer-kölcsönhatások feltárása, amely a gyógyszerfejlesztés korai időszakában kezdődik és végigkíséri a hatóanyagok életútját egészen a betegágyig. Monostory Katalin kutatómunkája során 1) primer májmodelleken alapuló, többszintű vizsgálati rendszert honosított meg és fejlesztett tovább, amely alkalmasnak bizonyult gyógyszer-hatóanyagok farmakokinetikai, metabolizmus és gyógyszer-interakciós sajátságainak feltérképezésére. 2) Rávilágított arra, hogy a gyógyszer-metabolizmusban kulcs-szerepet játszó citokróm P450 (CYP) enzimek variabilitása az egyes izoenzimeknél eltérő mértékben magyarázható a genetikai polimorfizmussal és a fenokonverziót kiváltó CYP-szelektív (CYP-gátlás és indukció) és nem-szelektív (pl. krónikus alkohol fogyasztás, amoxicillin+klavulánsav terápia) hatásokkal. 3) Diagnosztikai eljárást (CYPtestTM) dolgozott ki a betegek gyógyszer-metabolizáló képességének vérmintából történő meghatározására, amely a DNS analízissel megállapítható allélok kimutatásán (CYP-genotipizálás) és a leukocita CYP expresszióból történő CYP enzimaktivitás becslésen alapul. A CYP-státuszhoz igazított, személyre szabott terápia előnyei igazolódtak májátültetésen átesett betegek takrolimusz és epilepsziás gyermekek valproát kezelésében. Az új tudományos megállapítások nagyban hozzájárulnak a biztonságos és hatékony gyógyszeres terápia kialakításához.

Hivatkozás: https://mersz.hu/monostory-citokrom//

BibTeX EndNote Mendeley Zotero